Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Cytotoxic Therapy

Tumour Site

Presenters

Faroug Ali

Citation

Annals of Oncology (2020) 31 (suppl_6): S1241-S1254. 10.1016/annonc/annonc351

Authors

F.S. Ali1, N. Omar2, F. Calaud1, M.M. Elmistiri1, H. Ghazouani3, S. Bujassoum1, K.I. Rasul1

Author affiliations

  • 1 Medical Oncology, National Center for Cancer Care and Research - Hamad Medical Corporation (HMC), 3050 - Doha/QA
  • 2 Clinical Pharmacy, National Center for Cancer Care and Research, 3050 - Doha/QA
  • 3 Medical Statistics, National Center for Cancer Care and Research, 3050 - Doha/QA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 23P

Background

Oncotype DX RS estimates the likelihood of recurrence and predicts the benefit from chemotherapy in early HR positive, node negative breast cancer. Patients are categorized into one of three tiers based on a calculated recurrence score (RS); low (<18), intermediate (18–30), and high (≥31–100). 2008 NCCN guidelines recommended adjuvant endocrine therapy for low RS, adjuvant chemoendocrine therapy for high RS. There was no clear chemotherapy recommendation for intermediate RS. In 2018 the TAILORx re-established RS categories; a score of less than 11 is low, 11-25 is intermediate and 26-100 is high, and provided evidence to treat patients with intermediate RS. We are Studying Oncotype Dx RS correlation with clinic-pathologic risk factors, and chemotherapy based on TAILORx tiers. We also looked the characteristics of patients with cancer recurrence.

Methods

Retrospective review of patients who had Oncotype DX test during 2012-2017 at National Cancer Center–Qatar.

Results

Of 54 patients studied 16(29.63%) had low RS, 32(59.26%) had intermediate RS, and 6(11.1%) had high RS. Univariate analysis showed that age (p<0.014), tumor grade (p<0.034), and Ki67% (cut-off 20%; p<0.013) were significantly different among Oncotype DX RS categories. There was no significant difference among Oncotype DX RS categories for tumor size (p<0.288) or PR status (cut-off 1%, p<0.3). Multivariate analysis showed that none of the clinical/pathological factors significantly predict the Oncotype DX RS. Chemotherapy was given to 1/16 (6.25%) patients with low, 7/32(21.9%) patients with intermediate, and 4/6 (66.7%) patients with high Oncotype DX RS (univariate analysis p<0.01). Tumor size was the only predictor of chemotherapy in multivariate analysis (OR 2.33 CI 0.33 - 3.86, p<0.020). 75% of patients who relapsed had RS 16-25, and were less than 50 years old in age.

Conclusions

Oncotype RS correlates significantly with individual clinical risk factors including age, tumor grade, Ki67%, chemotherapy treatment. Tumor size significantly predicts adjuvant chemotherapy. Breast cancer recurrence was noticed in younger patients with high intermediate RS (16-25), and adjuvant chemotherapy may be a reasonable option for these patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.